Stem Cell Augmented, Elutriated Grafts for Allogeneic Bone Marrow Transplantation
Stem Cell Augmented, Elutriated Grafts for Allogeneic Bone Marrow Transplantation
RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells. Sometimes the transplanted cells can make an immune response against the body's normal tissues. Stem cells that have been treated in the laboratory to remove lymphocytes may prevent this from happening.
PURPOSE: Clinical trial to prevent graft-versus-host disease in patients undergoing bone marrow transplantation.
OBJECTIVES:
OUTLINE: Patients receive elutriated CD34+ augmented donor bone marrow on day 0.
Bone marrow samples are obtained before day 100, around 6 months, and 1 year after transplant.
PROJECTED ACCRUAL: Not specified
DISEASE CHARACTERISTICS:
Histologically confirmed diagnosis of one the following:
Must meet all inclusion criteria specified by the respective preparative regimen protocol
No aplastic anemia under 40 years of age or myelofibrosis
PATIENT CHARACTERISTICS:
Age:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery: